Altis Labs Raises US$25 Million Series A to Accelerate AI Endpoints in Oncology Trials

Altis Labs has closed a US$25 million Series A financing round co-led by OrbiMed and Qiming Venture Partners USA to expand its AI models for oncology trials and scale commercial deployment with biopharmaceutical partners. The funding will support Altis' AI endpoint technology, which uses survival predictions from radiology scans to detect treatment effects earlier than conventional imaging measures. In a Johnson & Johnson post-hoc analysis, Altis' IPRO model detected a significant treatment effect 11 months before the primary progression-free survival readout. Altis Labs trains its AI models on a multimodal oncology database spanning over 500,000 patient years, and top 20 biopharma companies currently use IPRO to analyze clinical trial data across phases 1-4.